公开(公告)号：US20190334861A1

公开(公告)日：2019-10-31

申请号：US16508269

申请日：2019-07-10

Applicant: Jing XU ,  ADHOCLINK TECHNOLOGIES WUHAN INC.

Inventor： Jing XU

IPC: H04L29/12

Abstract: The disclosure belongs to wireless communication technology, and the provided method, device and system of Forward Addressing and Backward Readdressing InterConnect (FABRIC) including, the method of forward addressing and backward readdressing interconnect enables any two devices in the system to establish interconnection channels when data exchange is required, and screens out suitable relay devices among the numerous intermediate devices between the two devices, the transmission of data is controlled within a limited range, and the interconnection channel is not unique, each time of data transmission is likely to pass through different intermediate devices with randomness and redundancy, it can cope with a certain degree of device movements. A plurality of devices can carry out communication between two at the same time without conflict.

公开(公告)号：US20120100099A1

公开(公告)日：2012-04-26

申请号：US13275205

申请日：2011-10-17

Applicant: Haitao WANG ,  Longbin LIU ,  Rui ZHANG ,  Jing XU ,  Yong DU

Inventor： Haitao WANG ,  Longbin LIU ,  Rui ZHANG ,  Jing XU ,  Yong DU

IPC: A61K38/19 ,  C12N9/48 ,  A61P43/00 ,  C12N5/10 ,  C12N15/62 ,  C07K19/00 ,  C12P21/00

CPC classification number: C12N15/62 ,  A61K47/6811 ,  A61K47/6835 ,  C07K2317/53 ,  C07K2319/30

Abstract: A fusion protein having a non-immunoglobulin polypeptide having a cysteine residue proximal to the C terminal thereof, and an immunoglobulin component with a mutated hinge region is provided. The mutation comprises a point mutated site corresponding in position to the position in a native hinge region of the cysteine residue located nearest the cysteine residue of the non-Ig component. The distance from the cysteine residue of the non-immunoglobulin polypeptide and any remaining cysteine residues of the mutated hinge region is sufficient to prevent the formation of a disulphide bond therebetween.

Abstract translation: 提供了具有非免疫球蛋白多肽的融合蛋白，其具有接近其C末端的半胱氨酸残基和具有突变的铰链区的免疫球蛋白组分。 该突变包括位于位于最接近非Ig组分的半胱氨酸残基的半胱氨酸残基的天然铰链区的位置的点突变位点。 与非免疫球蛋白多肽的半胱氨酸残基和突变的铰链区的任何剩余半胱氨酸残基的距离足以防止其间形成二硫键。

公开(公告)号：US20130224198A1

公开(公告)日：2013-08-29

申请号：US13872790

申请日：2013-04-29

Applicant: Haitao WANG ,  Yong DU ,  Rui ZHANG ,  Jing XU ,  Longbin LIU

Inventor： Haitao WANG ,  Yong DU ,  Rui ZHANG ,  Jing XU ,  Longbin LIU

IPC: A61K47/48 ,  C07K14/505

CPC classification number: C07K14/505 ,  A61K9/0019 ,  A61K38/00 ,  A61K47/6811 ,  C07K2317/53 ,  C07K2319/30

Abstract: A recombinant fusion protein comprising a human erythropoietin peptide portion linked to an immunoglobulin peptide portion is described. The fusion protein has a prolonged half-life in vivo compared to naturally occurring or recombinant native human erythropoietin. In one embodiment, the protein has a half-life in vivo at least three-fold higher than native human erythropoietin. The fusion protein exhibits enhanced erythropoietic bioactivity compared to native human erythropoietin. In one embodiment, the fusion protein comprises the complete peptide sequence of a human erythropoietin (EPO) molecule and the peptide sequence of an Fc fragment of human IgG1, which Fc fragment includes the hinge region, CH2 and CH3 domains. The EPO molecule may be linked directly to the Fc fragment to avoid extraneous peptide linkers and lessen risk of an immunogenic response when administered. In one embodiment the hinge region is a human Fc fragment variant having a non-cysteine residue at amino acid 6.

Abstract translation: 描述了包含与免疫球蛋白肽部分连接的人促红细胞生成素肽部分的重组融合蛋白。 与天然存在的或重组的天然人促红细胞生成素相比，融合蛋白具有延长的体内半衰期。 在一个实施方案中，蛋白质的体内半衰期比天然人促红细胞生成素高至少三倍。 与天然人促红细胞生成素相比，融合蛋白表现出增强的红细胞生物活性。 在一个实施方案中，融合蛋白包含人促红细胞生成素（EPO）分子的完整肽序列和人IgG1的Fc片段的肽序列，所述Fc片段包括铰链区，CH2和CH3结构域。 EPO分子可以直接连接到Fc片段，以避免外来的肽接头，并且当施用时降低免疫原性反应的风险。 在一个实施方案中，铰链区是在氨基酸6具有非半胱氨酸残基的人Fc片段变体。

公开(公告)号：US20100099145A1

公开(公告)日：2010-04-22

申请号：US12555742

申请日：2009-09-08

Applicant: Haitao WANG ,  Chungsheng Mao ,  Jizhi Li ,  Jing XU ,  Rui ZHANG ,  Ling Wang ,  Yong Du ,  Longbin LIU

Inventor： Haitao WANG ,  Chungsheng Mao ,  Jizhi Li ,  Jing XU ,  Rui ZHANG ,  Ling Wang ,  Yong Du ,  Longbin LIU

IPC: C12P21/00 ,  C07H21/04 ,  C12N5/16

CPC classification number: C07K14/505 ,  A61K9/0019 ,  A61K38/00 ,  A61K47/6811 ,  C07K2317/53 ,  C07K2319/30

Abstract: A recombinant fusion protein comprising a human erythropoietin peptide portion linked to an immunoglobulin peptide portion is described. The fusion protein has a prolonged half-life in vivo in comparison to naturally occurring or recombinant native human erythropoietin. In one embodiment of the invention, the protein has a half-life in vivo at least three fold higher than native human erythropoietin. The fusion protein also exhibits enhanced erythropoietic bioactivity in comparison to native human erythropoietin. In one embodiment, the fusion protein comprises the complete peptide sequence of a human erythropoietin (EPO) molecule and the peptide sequence of an Fc fragment of human immunoglobulin IgG1. The Fc fragment in the fusion protein includes the hinge region, CH2 and CH3 domains of human immunoglobulin IgG1. The EPO molecule may be linked directly to the Fc fragment to avoid extraneous peptide linkers and lessen the risk of an immunogenic response when administered in vivo. In one embodiment the hinge region is a human Fc fragment variant having a non-cysteine residue at amino acid 6. The invention also relates to nucleic acid and amino acid sequences encoding the fusion protein and transfected cell lines and methods for producing the fusion protein. The invention further includes pharmaceutical compositions comprising the fusion protein and methods of using the fusion protein and/or the pharmaceutical compositions, for example to stimulate erythropoiesis in subjects in need of therapy.

公开(公告)号：US20100099612A1

公开(公告)日：2010-04-22

申请号：US12555759

申请日：2009-09-08

Applicant: Haitao WANG ,  Chungsheng MAO ,  Jizhi LI ,  Jing XU ,  Rui ZHANG ,  Ling WANG ,  Yong DU ,  Longbin LIU

Inventor： Haitao WANG ,  Chungsheng MAO ,  Jizhi LI ,  Jing XU ,  Rui ZHANG ,  Ling WANG ,  Yong DU ,  Longbin LIU

IPC: A61K38/16 ,  A61P35/00 ,  A61P31/12

CPC classification number: C07K14/56 ,  A61K38/00 ,  C07K14/555

Abstract: This application relates to recombinant human interferon-like proteins. In one embodiment a recombinant protein created by gene shuffling technology is described having enhanced anti-viral and anti-proliferative activities in comparison to naturally occurring human interferon alpha 2b (HuIFN-α2b). The invention encompasses a polynucleotide encoding the protein and recombinant vectors and host cells comprising the polynucleotide. Preferably the polynucleotide is selected from the group of polynucleotides each having a sequence at least 93% identical to SEQ ID: No. 1 and the protein is selected from the group of proteins each having an amino acid sequence at least 85% identical to SEQ ID No: 2. The proteins and compositions comprising the proteins can be used for treatment of conditions responsive to interferon therapy, such as viral diseases and cancer.

Abstract translation: 本申请涉及重组人类干扰素样蛋白。 在一个实施方案中，与天然存在的人类干扰素α2b（HuIFN-α2b）相比，描述了通过基因改组技术产生的重组蛋白质具有增强的抗病毒和抗增殖活性。 本发明包括编码蛋白质的多核苷酸和包含多核苷酸的重组载体和宿主细胞。 优选地，多核苷酸选自各自具有与SEQ ID：No.1至少93％相同的序列的多核苷酸，并且所述蛋白质选自蛋白质组，其各自具有与SEQ ID NO：至少85％相同的氨基酸序列 否：2.包含蛋白质的蛋白质和组合物可用于治疗对干扰素治疗（例如病毒性疾病和癌症）有反应的病症。

公开(公告)号：US20130226842A1

公开(公告)日：2013-08-29

申请号：US13445796

申请日：2012-04-12

Applicant: Yea J. CHU ,  Sier HAN ,  Jing-Yun SHYR ,  Jing XU

Inventor： Yea J. CHU ,  Sier HAN ,  Jing-Yun SHYR ,  Jing XU

IPC: G06F15/18

CPC classification number: G06N5/025 ,  G06F15/18 ,  G06N5/04 ,  G06N99/005

Abstract: Provided are techniques for imputing a missing value for each of one or more predictor variables. Data is received from one or more data sources. For each of the one or more predictor variables, an imputation model is built based on information of a target variable; a type of imputation model to construct is determined based on the one or more data sources, a measurement level of the predictor variable, and a measurement level of the target variable; and the determined type of imputation model is constructed using basic statistics of the predictor variable and the target variable. The missing value is imputed for each of the one or more predictor variables using the data from the one or more data sources and one or more built imputation models to generate a completed data set.

Abstract translation: 提供了用于估算每个一个或多个预测变量的缺失值的技术。 从一个或多个数据源接收数据。 对于一个或多个预测变量中的每一个，基于目标变量的信息构建插补模型; 基于一个或多个数据源，预测变量的测量水平和目标变量的测量水平来确定构造的插补模型的类型; 并使用预测变量和目标变量的基本统计量构建确定的插补模型。 使用来自一个或多个数据源的数据和一个或多个内置插补模型来为每个一个或多个预测变量估计缺失值，以生成完成的数据集。

公开(公告)号：US20130226838A1

公开(公告)日：2013-08-29

申请号：US13403863

申请日：2012-02-23

Applicant: Yea J. CHU ,  Sier HAN ,  Jing-Yun SHYR ,  Jing XU

Inventor： Yea J. CHU ,  Sier HAN ,  Jing-Yun SHYR ,  Jing XU

IPC: G06F15/18

CPC classification number: G06N5/025 ,  G06F15/18 ,  G06N5/04 ,  G06N99/005

Abstract: Provided are techniques for imputing a missing value for each of one or more predictor variables. Data is received from one or more data sources. For each of the one or more predictor variables, an imputation model is built based on information of a target variable; a type of imputation model to construct is determined based on the one or more data sources, a measurement level of the predictor variable, and a measurement level of the target variable; and the determined type of imputation model is constructed using basic statistics of the predictor variable and the target variable. The missing value is imputed for each of the one or more predictor variables using the data from the one or more data sources and one or more built imputation models to generate a completed data set.

公开(公告)号：US20130200714A1

公开(公告)日：2013-08-08

申请号：US13364550

申请日：2012-02-02

Applicant: Jiuping PAN ,  Hongrae KIM ,  Jun LI ,  Jing XU ,  Jyoti SASTRY ,  Waqas ARSHAD

Inventor： Jiuping PAN ,  Hongrae KIM ,  Jun LI ,  Jing XU ,  Jyoti SASTRY ,  Waqas ARSHAD

IPC: H02J1/12

CPC classification number: H02J1/102 ,  H02J3/36 ,  H02J3/386 ,  H02J4/00 ,  H02M2007/4835 ,  Y02E10/763 ,  Y02E60/60 ,  Y10T307/707

Abstract: A power generation system includes at least one generator having at least two sets of stator windings, an active rectifier comprising power cell based modular converters associated with each set of generator windings. Each set of windings is connected to an AC voltage side of the associated active rectifier, with each active rectifier having a positive DC voltage output and a negative DC voltage output. The DC voltage outputs of active rectifiers are connected to each other in series. A medium voltage DC (MVDC) collection network comprises positive pole cables and negative pole cables, wherein each positive pole cable is connected to the positive DC voltage output of a first active rectifier and each negative pole cable is connected to the negative DC voltage output of a last active rectifier. A substation receives the negative and positive pole cables of the MVDC collection network for further transformation and transmission.

Abstract translation: 发电系统包括具有至少两组定子绕组的至少一个发电机，包括与每组发电机绕组相关联的基于功率单元的模块转换器的有源整流器。 每组绕组连接到相关的有源整流器的AC电压侧，每个有源整流器具有正的直流电压输出和负的直流电压输出。 有源整流器的直流电压输出串联连接。 中压直流（MVDC）采集网络包括正极电缆和负极电缆，其中每个正极电缆连接到第一有源整流器的正直流电压输出，每个负极电缆连接到负极直流电压输出 最后一个有源整流器。 变电站接收MVDC收集网络的负极和正极电缆，用于进一步的变换和传输。

公开(公告)号：US20100098716A1

公开(公告)日：2010-04-22

申请号：US12555743

申请日：2009-09-08

Applicant: Haitao WANG ,  Chungsheng Mao ,  Jizhi Li ,  Jing XU ,  Rui ZHANG ,  Ling Wang ,  DU Yong ,  Longbin LIU

Inventor： Haitao WANG ,  Chungsheng Mao ,  Jizhi Li ,  Jing XU ,  Rui ZHANG ,  Ling Wang ,  DU Yong ,  Longbin LIU

IPC: A61K39/395 ,  A61K38/00

CPC classification number: C07K14/505 ,  A61K9/0019 ,  A61K38/00 ,  A61K47/6811 ,  C07K2317/53 ,  C07K2319/30

Abstract: A recombinant fusion protein comprising a human erythropoietin peptide portion linked to an immunoglobulin peptide portion is described. The fusion protein has a prolonged half-life in vivo in comparison to naturally occurring or recombinant native human erythropoietin. In one embodiment of the invention, the protein has a half-life in vivo at least three fold higher than native human erythropoietin. The fusion protein also exhibits enhanced erythropoietic bioactivity in comparison to native human erythropoietin. In one embodiment, the fusion protein comprises the complete peptide sequence of a human erythropoietin (EPO) molecule and the peptide sequence of an Fc fragment of human immunoglobulin IgG1. The Fc fragment in the fusion protein includes the hinge region, CH2 and CH3 domains of human immunoglobulin IgG1. The EPO molecule may be linked directly to the Fc fragment to avoid extraneous peptide linkers and lessen the risk of an immunogenic response when administered in vivo. In one embodiment the hinge region is a human Fc fragment variant having a non-cysteine residue at amino acid 6. The invention also relates to nucleic acid and amino acid sequences encoding the fusion protein and transfected cell lines and methods for producing the fusion protein. The invention further includes pharmaceutical compositions comprising the fusion protein and methods of using the fusion protein and/or the pharmaceutical compositions, for example to stimulate erythropoiesis in subjects in need of therapy.

Abstract translation: 描述了包含与免疫球蛋白肽部分连接的人促红细胞生成素肽部分的重组融合蛋白。 与天然存在的或重组的天然人促红细胞生成素相比，融合蛋白在体内具有延长的半衰期。 在本发明的一个实施方案中，蛋白质的体内半衰期比天然人促红细胞生成素高至少三倍。 与天然人促红细胞生成素相比，融合蛋白也表现出增强的红细胞生物活性。 在一个实施方案中，融合蛋白包含人促红细胞生成素（EPO）分子的完整肽序列和人免疫球蛋白IgG1的Fc片段的肽序列。 融合蛋白中的Fc片段包括人免疫球蛋白IgG1的铰链区，CH2和CH3结构域。 EPO分子可以直接连接到Fc片段，以避免外来的肽接头并且当在体内施用时减轻免疫原性应答的风险。 在一个实施方案中，铰链区是在氨基酸6具有非半胱氨酸残基的人Fc片段变体。本发明还涉及编码融合蛋白和转染细胞系的核酸和氨基酸序列以及用于产生融合蛋白的方法。 本发明还包括包含融合蛋白的药物组合物和使用融合蛋白和/或药物组合物的方法，例如刺激需要治疗的受试者的红细胞生成。

公开(公告)号：US20090081218A1

公开(公告)日：2009-03-26

申请号：US12180455

申请日：2008-07-25

Applicant: Haitao WANG ,  Yong DU ,  Rui ZHANG ,  Jing XU ,  Longbin LIU

Inventor： Haitao WANG ,  Yong DU ,  Rui ZHANG ,  Jing XU ,  Longbin LIU

IPC: A61K39/395 ,  C07K16/18 ,  C12N9/50 ,  C07H21/04 ,  C12P21/04 ,  C12N5/06

CPC classification number: C12N15/62 ,  A61K47/6811 ,  A61K47/6835 ,  C07K2317/53 ,  C07K2319/30

Abstract: A fusion protein having a non-immunoglobulin polypeptide having a cysteine residue proximal to the C terminal thereof, and an immunoglobulin component with a mutated hinge region is provided. The mutation comprises a point mutated site corresponding in position to the position in a native hinge region of the cysteine residue located nearest the cysteine residue of the non-Ig component. The distance from the cysteine residue of the non-immunoglobulin polypeptide and any remaining cysteine residues of the mutated hinge region is sufficient to prevent the formation of a disulphide bond therebetween.

Abstract translation: 提供了具有非免疫球蛋白多肽的融合蛋白，其具有接近其C末端的半胱氨酸残基和具有突变的铰链区的免疫球蛋白组分。 该突变包括位于位于最接近非Ig组分的半胱氨酸残基的半胱氨酸残基的天然铰链区的位置的点突变位点。 与非免疫球蛋白多肽的半胱氨酸残基和突变的铰链区的任何剩余半胱氨酸残基的距离足以防止其间形成二硫键。